Cart
sales@molnova.com
CPI-1189
CAS No. 183619-38-7
CPI-1189( CPI-1189 | REN-1189 | REN-1654 | REN1189 )
Catalog No. M17393 CAS No. 183619-38-7
REN-1189 is a TNF-a release inhibitor potentially for the treatment of sciatica and postherpetic neuralgia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 10MG | 36 | In Stock |
|
| 25MG | 79 | In Stock |
|
| 50MG | 127 | In Stock |
|
| 100MG | 211 | In Stock |
|
| 200MG | 310 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCPI-1189
-
NoteResearch use only, not for human use.
-
Brief DescriptionREN-1189 is a TNF-a release inhibitor potentially for the treatment of sciatica and postherpetic neuralgia.
-
DescriptionREN-1189 is a TNF-a release inhibitor potentially for the treatment of sciatica and postherpetic neuralgia.
-
In VitroCell Viability Assay Cell Line:SH-SY5Y oncentration:10, 30, 100, 300 nM Incubation Time:1 h Result:Alleviated OGDR-induced cytotoxicity in a concentration-dependent manner.Apoptosis Analysis Cell Line:SH-SY5Y Concentration:100 nM Incubation Time:1 h Result:Inhibited OGDR-induced caspase-3/-9 activation and ssDNA accumulation.Attenuated OGDR-induced apoptosis activation.
-
In Vivo——
-
SynonymsCPI-1189 | REN-1189 | REN-1654 | REN1189
-
PathwayOthers
-
TargetOther Targets
-
RecptorTNF-α
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number183619-38-7
-
Formula Weight234.3
-
Molecular FormulaC13H18N2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (426.82 mM)
-
SMILESCC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C
-
Chemical Name4-acetamido-N-(tert-butyl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bjugstad KB,et al. Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 1998 Jun 8;795(1-2):349-57.
molnova catalog
related products
-
Pilloin
Pilloin exerts a cytotoxic action targeted at the transformed lymphoblasts.
-
Collagen proline hyd...
Collagen proline hydroxylase inhibitor-1 exhibits antifibroproliferative activity.
-
Litifilimab
Litifilimab, a humanized IgG1-κ antibody, targets the C-type lectin domain family 4 member C (CLEC4C) and has potential applications in the study of cutaneous lupus erythematosus (CLE) .
